July 07, 2015
Below are current clinical trials.17 studies in Parkinson's disease
(open studies only).
Filter this list of studies by location, status and more.
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced, levodopa-responsive bilateral Parkinson's disease (PD) which is not adequately controlled with medication.
The purpose of this study is ongoing longitudinal clinicopathologic studies of normal aging and Parkinson's Disease subjects. Specific projects of motor, non-motor and peripheral manifestations of Parkinson’s disease (PD) as possible early markers of PD onset in otherwise asymptomatic elderly people. Cognitive and non-cognitive markers of eventual dementia onset in previously non-demented persons with PD.
The purpose of this proposal is to explore whether the presence of Lewy pathology in the gastrointestinal tract is associated with functional disturbances such as constipation and dysphagia in both Parkinson’s disease patients and non-Parkinson’s disease patients, and if present in the latter patients whether this relates to the subsequent development of Parkinson’s disease.
The purpose of this study is to compare treadmill walking and over ground walking gait characteristics in people diagnosed with Parkinson’s disease.
Primary Objectives: - Part 1: To determine the safety and tolerability of GZ/SAR402671 administered orally, as compared to placebo in patients with early-stage Parkinson's disease (PD) carrying a GBA mutation or other pre-specified variants. - Part 2: To determine the efficacy of GZ/SAR402671 administered orally daily, as compared to placebo in patients with early-stage Parkinson's disease carrying a GBA mutation or other pre-specified variants. Secondary Objectives: Part 1: - To assess the pharmacokinetic (PK) profile of oral dosing of GZ/SAR4027671 in plasma when administered in early-stage Parkinson's disease patients carrying a GBA mutation. - To assess the exposure of GZ/SAR402671 in cerebrospinal fluid (CSF) when administered in early-stage Parkinson's disease patients carrying a GBA mutation. Part 2: - To demonstrate overall safety and tolerability of GZ/SAR4027671 administered orally in early-stage Parkinson's disease patients carrying a GBA mutation as compared to placebo. - To assess the pharmacodynamic response to daily oral dosing of GZ/SAR402671 in plasma and CSF as measured by glucosylceramide (GL-1) when administered in early-stage Parkinson's disease patients carrying a GBA mutation.
The purpose of this study is to learn more about Lewy Body disease and a skin condition called Bullous Pemphigoid.
This study will determine the validity of predictive and surrogate biomarkers for the detection of Parkinson's disease and Parkinson's disease cognitive decline.
The potential role of Small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with PD has not previously been examined. Our hypothesis is that SBBO is an important contributor to the development of weight loss in individuals with Parkinson's disease. The investigators propose to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators propose to perform a prospective, observational case-control study with an open-label therapeutic component. Cases will be defined as those PD patients who've experienced significant weight loss while Controls will be defined as those PD patients who have not experienced significant weight loss.
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.
The purpose of this study is to determine whether oral inosine dosed to moderately elevate serum urate (from ≤5.7 mg/dL to 7.1-8.0 mg/dL) over 2 years slows clinical decline in early Parkinson's disease.
- Longo DL, et al. Parkinson's disease and other movement disorders. In: Harrison's Principles of Internal Medicine. 18th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://accessmedicine.com. Accessed April 6, 2015.
- Parkinson's disease: Hope through research. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm. Accessed April 6. 2015.
- Ferri FF. Parkinson's disease. In: Ferri's Clinical Advisor 2015: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed April 6, 2015.
- Chou KL. Diagnosis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Tarsy D. Pharmacologic treatment of Parkinson disease. http://www.uptodate.com/home. Accessed April 6. 2015.
- Adler CH, et al. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology. 2014;82:858.
- Bousquet M, et al. Impact of omega-3 fatty acids in Parkinson's disease. Ageing Research Reviews. 2011;10:453.
- Parkinson's disease: Fitness counts. National Parkinson Foundation. http://www.parkinson.org/Search-Pages/Search.aspx?pKeywords=fitness. Accessed April 9, 2015.
- Parkinson's disease. Natural Medicines Comprehensive Database. http://www.naturaldatabase.com. Accessed April 6, 2015.
- Tarsy D. Nonpharmacologic management of Parkinson disease. http://www.uptodate.com/home/. Accessed April 6, 2015.
- Complementary therapies and Parkinson's. Parkinson's Disease Society of the United Kingdom. http://www.parkinsons.org.uk/content/complementary-therapies-and-parkinsons-booklet. Accessed April 9, 2015.
- Jankovic J. Etiology and pathogenesis of Parkinson disease. http://www.uptodate.com/home. Accessed April 6, 2015.
- Riggs EA. Decision Support System. Mayo Clinic, Rochester, Minn. April 16, 2015.
- Abbvie announces U.S. approval of duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson's disease. http://abbvie.mediaroom.com/2015-01-12-AbbVie-Announces-U-S-FDA-Approval-of-DUOPA-carbidopa-and-levodopa-Enteral-Suspension-for-the-Treatment-of-Motor-Fluctuations-in-Patients-with-Advanced-Parkinsons-Disease. Accessed April 20, 2015.
- Bower JH (expert opinion). Mayo Clinic, Rochester, Minn. April 20, 2015.